



BAFNA PHARMACEUTICALS LTD.,

REGD. OFFICE: "BAFNA TOWERS" 299, THAMBU CHETTY STREET, CHENNAI-600 001, INDIA.
PHONE:+044-25267517/25270992, FAX:91-44-25231264, Email: info@bafnapharma.com, website: www.bafnapharma.com
CIN: L24294TN1995PLC030698

BAFNA PHARMACEUTICALS LIMITED - (CIN L24294TN1995PLC030698)						
Regd office: 299, THAMBU CHETTY STREET, CHENNAI- 600 001						
Statement of Standalone Unaudited Financial Results for the Quarter and Half year Ended 30 th September 2015						
PART I			Rs. In Lakhs			
Particulars	STANDALONE					
	3 months ended (30-09-2015)	3 months ended (30-06-2015)	Corresponding 3 months ended in the previous year (30-09-2014)	Year to Date figures for current Period ended (30-09-2015)	Year to Date figures for the previous year ended (30-09-2014)	Previous Year Ended (31-03-2015)
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Income form Operations						
(a) Net Sales/Income from Operations (net of excise duty)	1,598.82	2,311.98	2,319.41	3,910.80	5,842.05	10,140.94
(b) Other Operating Income	-	-	4,176.54	-	4,176.54	4,111.07
Total income from operations (net)	1,598.82	2,311.98	6,495.95	3,910.80	10,018.59	14,252.02
2. Expenditure						
a. Cost of materials consumed	882.43	415.43	1,409.30	1,297.86	1,911.82	3,382.64
b. Purchase of stock-in-trade	473.17	1,431.13	165.69	1,904.30	1,790.24	4,785.89
c. Changes in inventories of finished goods,WIP and stock-in-trade	(214.79)	33.19	(86.13)	(181.60)	115.84	1,235.84
d. Employees benefits expense	165.55	159.35	277.19	324.90	629.57	1,034.29
e. Depreciation and amortisation expense	53.24	102.44	166.21	155.68	363.32	523.76
f. Other expenditure (Any item exceeding 10% of the total expenses relating to continuing operations)	152.27	71.61	325.91	223.88	605.81	1,278.77
Total Expenses	1,511.88	2,213.16	2,258.18	3,725.04	5,416.60	12,241.20
3. Profit/(Loss) from Operations before Other Income, finance cost and Exceptional Items (1-2)	86.94	98.82	4,237.77	185.76	4,601.99	2,010.82
4. Other Income	72.80	27.22	63.70	100.02	74.37	113.51
5. Profit/(Loss) from ordinary activities before finance cost and Exceptional Items (3+/- 4)	159.74	126.04	4,301.48	285.78	4,676.36	2,124.33
6. Finance Costs	376.67	237.87	405.16	614.54	738.04	1,247.63
7. Profit/(Loss) from ordinary activities after finance cost but before Exceptional Items (5+/- 6)	(216.93)	(111.83)	3,896.32	(328.76)	3,938.32	876.71
8. Exceptional items	-	-	268.81	-	268.81	268.81
9. Profit / Loss from Ordinary Activities before tax (7+/- 8)	(216.93)	(111.83)	3,627.51	(328.76)	3,669.51	607.90
10. Tax expense	23.90	7.44	305.58	31.34	316.64	(2.84)
11. Net Profit / Loss from Ordinary Activities after tax (9 +/- 10)	(240.83)	(119.27)	3,321.93	(360.10)	3,352.87	610.73
12. Extraordinary Item (net of tax expense Rs. _____ lacs)	-	-	-	-	-	-
13. Net Profit/ Loss for the period (11 +/- 12)	(240.83)	(119.27)	3,321.93	(360.10)	3,352.87	610.73
14. Share of profit/ (loss) of associates*	-	-	-	-	-	-
15. Minority Interest*	-	-	-	-	-	-
16. Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 +/- 14 +/- 15)*	(240.83)	(119.27)	3,321.93	(360.10)	3,352.87	610.73
17. Paid up equity share capital (Face value of Rs.10/- each)	1,865.63	1,865.63	1,865.63	1,865.63	1,865.63	1,865.63
18. Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	-
19 (i). Earnings Per Share (EPS) (before extraordinary items) (not annualised)						
a) Basic	(1.29)	(0.64)	17.81	(1.93)	17.97	3.27
b) Diluted	(1.29)	(0.64)	17.81	(1.93)	17.97	3.27
19 (ii). Earning per share (after extraordinary items) (not annualised)						
a) Basic	(1.29)	(0.64)	17.81	(1.93)	17.97	3.27
b) Diluted	(1.29)	(0.64)	17.81	(1.93)	17.97	3.27

Factory: UNIT-I : 13, S.V. KOIL STREET, MADHAVARAM, CHENNAI-60, INDIA. PHONE: +044-25530329/25531965, E mail: factory@bafnapharma.com
UNIT-II : 147, Madhavaram Redhills High Road, Grantlyon Village, Vadakarai Post, Chennai-600 052. Phone: +044-26322900, E mail: factory1@bafnapharma.com





BAFNA PHARMACEUTICALS LTD.,


REGD. OFFICE: "BAFNA TOWERS" 299, THAMBU CHETTY STREET, CHENNAI-600 001, INDIA.
 PHONE:+044-25267517/25270992, FAX:91-44-25231264, Email: info@bafnapharma.com, website: www.bafnapharma.com
 CIN: L24294TN1995PLC030698

Part II Particulars	STANDALONE					
	3 months ended	Preceding 3 Months Ended	Corresponding 3 months ended in the previous year	Year to Date figures for current Period ended	Year to Date figures for the previous year ended	Previous year ended
	(30-09-2015)	(30-06-2015)	(30-09-2014)	(30-09-2015)	(30-09-2014)	(31-03-2015)
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
A. Particulars of Shareholding						
1.Public Shareholding						
- No. of shares	12,334,805	11,892,412	11,762,838	12,334,805	11,762,838	11,805,566
- Percentage of shareholding	66.12	63.74	63.05	66.12	63.05	63.28
2. Promoters and promoter group shareholding**						
a) Pledged/Encumbered						
- Number of shares	1,397,736	1,397,736	1,530,000	1,397,736	1,530,000	1,397,736
- Percentage of shares (as a% of the total shareholding of promoter and promoter group)	22.11	20.66	22.19	22.11	22.19	20.40
- Percentage of shares (as a% of the total share capital of the Company)	7.49	7.49	8.65	7.49	8.20	7.49
b) Non-encumbered						
- Number of Shares	4,923,794	5,366,187	5,363,497	4,923,794	5,363,497	5,453,033
- Percentage of shares (as a% of the total shareholding of promoter and promoter group)	77.89	79.34	77.81	77.89	77.81	79.60
- Percentage of shares (as a % of the total share capital of the company)	26.39	26.76	28.75	26.39	28.75	29.23

NOTES

- The above unaudited quarterly financial results were reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at their Meeting held on 06.11.2015
- Status of Investor Complaints:
 Opening balance Nil
 Pending at the beginning of the quarter Nil
 No. of complaints received and disposed off during the quarter Nil
 Complaints pending at the end of the quarter Nil
- The Company operates only in one segment, ie. Pharmaceutical formulations, as such reporting is done on a single segment basis.
- The Limited Review as required under Clause 41 of the Listing Agreement has been completed by the statutory Auditors for the Quarter ended 30.09.2015
- The Revised Schedule VI has become applicable to the Company for the presentation of Financial statement, accordingly the previous year/ period figures have been regrouped / reclassified wherever necessary
- The MD and Manager-Accounts & Finance certificate in respect of the above results in terms of the requirement of Clause 41 of the Listing Agreement has been placed before the Board of Directors.
- The figures of the Quarter are the balancing figures in respect of the Financial year and the published year to date figures upto the Second quarter of the Financial year.

For BAFNA PHARMACEUTICALS LIMITED


 BAFNA MAHAVEER CHAND
 MANAGING DIRECTOR

Place : Chennai
 Date : 06.11.2015



BAFNA PHARMACEUTICALS LTD.,

REGD. OFFICE: "BAFNA TOWERS" 299, THAMBU CHETTY STREET, CHENNAI-600 001, INDIA.
PHONE:+044-25267517/25270992, FAX:91-44-25231264, Email: info@bafnapharma.com, website: www.bafnapharma.com
CIN: L24294TN1995PLC030698

ANNEXURE II

STANDALONE STATEMENT OF ASSETS AND LIABILITIES AS AT 30th SEPTEMBER 2015		
(Rs. In Lakhs)		
Particulars	STANDALONE	
	As at 30th September 2015	As at 31st March 2015
	(Unaudited)	(Audited)
A. Equity and Liabilities		
1. Shareholders funds		
a) Share Capital	1,865.63	1,865.63
b) Reserves and surplus	4,937.18	5,297.28
c) Money received against share warrants	-	-
Sub -Total- Shareholders' Funds	6,802.81	7,162.91
2. Share Application money pending allotment		
3. Minority Interest *		-
4. Non - Current Liabilities		
a) Long term borrowings	1,332.05	1,039.31
b) Deffered tax Liabilites (net)	399.46	368.10
c) Other long term liabilities	3.00	3.00
d) Long term provisions		
Sub -Total- Non Current Liabilities	1,734.51	1,410.41
5. Current Liabilities		
a) Short- term borrowings	6,120.43	5,330.58
b) Trade payables	2,604.73	3,465.47
c) Other current liabilities	1,216.73	1,156.45
d) Short term provisions	-	-
Sub -Total-Current Liabilities	9,941.89	9,952.51
Total- Equity and Liabilities	18,479.21	18,525.83
B. Assets		
1. Non current Assets		
a) Fixed Assets	4,795.28	4,862.95
b) Intangible Assets		
c) Goodwill on consolidation*		
d) Non - current investments	1,833.00	1,833.00
e) Defered tax assets (net)		
e) Long term loans and advances		
f) Other non current assets	80.64	86.23
Sub -Total- Non Current Assets	6,708.92	6,782.18
2. Current Assets		
a) Current Investments	-	-
b) Inventories	1,587.78	1,532.98
c) Trade receivables	8,198.89	8,336.39
d) Cash and cash equivalents	304.91	244.93
e) Short term loans and advances	1,678.71	1,629.35
f) Other current Assets	-	-
Sub -Total- Current Assets	11,770.29	11,743.65
Total - Assets	18,479.21	18,525.83

Factory: UNIT-I : 13, S.V. KOIL STREET, MADHAVARAM, CHENNAI-60, INDIA. PHONE: +044-26322900/25531965, E mail: factory@bafnapharma.com

UNIT-II : 147, Madhavaram Redhills High Road, Granlityon Village, Vadakarai Post, Chennai-600 052. Phone: +044-26322900, E mail: factory1@bafnapharma.com